PRINCETON, N.J., Nov. 17, 2015 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products, today announced that Al Altomari, President and Chief Executive...
Agile Plans to Increase Twirla prescriptions filled through telemedicine platforms that utilize vitaCare, such as Twentyeight Health™ Partnership Expected to Augment Future Growth in the Retail Channel, the Company’s Most-Profitable Channel Expanding Commercial Reach through Strategic Partnerships...
Once-Weekly Twirla is the first and only contraceptive patch that combines levonorgestrel and ethinyl estradiol (EE) PRINCETON, N.J. , Dec. 07, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced the U.S....
PRINCETON, N.J. , Aug. 08, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced that the underwriters of its previously announced public offering of common stock have exercised in full their option to purchase an additional 1,894,736...
29% increase in Twirla cycles 27% increase in total prescriptions (TRx) of Twirla PRINCETON, N.J., April 14, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced Twirla prescription data for the first quarter 2022....
PRINCETON, N.J., May 05, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today publicly released the findings of its first year of post-marketing pharmacovigilance safety surveillance for Twirla ® (levonorgestrel and ethinyl estradiol) transdermal...
PRINCETON, N.J. , Nov. 14, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced that the U.S. Food and Drug Administration ( FDA ) has extended the Prescription Drug User Fee Act (PDUFA) goal date for its review of the New Drug Application...
